In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 80 days of free consultation

 

Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study

Session Poster Session 7

Speaker Joan Elias Walter

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease - Diagnostic Methods
  • Session type : Poster Session
  • FP Number : P6436

Authors : J E Walter (Basel,CH), M Amrein (Basel,CH), L Koechlin (Basel,CH), J Du Fay De Lavallaz (Basel,CH), T Zimmermann (Basel,CH), R Twerenbold (Basel,CH), C Mueller (Basel,CH)

Authors:
J E Walter1 , M Amrein1 , L Koechlin1 , J Du Fay De Lavallaz1 , T Zimmermann1 , R Twerenbold1 , C Mueller1 , 1University Hospital Basel, Cardiovascular Research Institute Basel - Basel - Switzerland ,

On behalf: BASEL VIII

Citation:

Background: The urokinase system is pivotal in the pathogenesis of atherosclerosis. Therefore, soluble urokinase plasminogen activator receptor (suPAR) concentrations may help in the detection of functionally relevant coronary artery disease (fCAD).

Purpose: To evaluate suPAR as diagnostic marker for fCAD.

Methods: Among consecutive patients with symptoms suggestive of fCAD, fCAD was adjudicated blinded to suPAR concentrations in two domains: first, diagnosis of fCAD according to myocardial perfusion single photon emission tomography (MPI-SPECT) and coronary angiography; second, fCAD according to cardiovascular death, non-fatal acute myocardial infarction (AMI) and all-cause death during 2-year follow-up.

Results: Among 968 patients, symptoms were adjudicated to be causally related to fCAD in 26% (255/968). SuPAR concentrations were higher in patients with fCAD as compared to those without (3.45 ng/mL versus 3.20 ng/mL, p=0.007), but overall had only low diagnostic accuracy (area under the curve [AUC]: 0.56, 95%CI 0.52-0.60) and were not independent predictors of fCAD after multivariable adjustment. Circulating suPAR concentrations were modestly correlated with high-sensitivity cardiac troponin (hs-cTn) T (Spearman’s rho 0.393, p<0.001), NT-proBNP (Spearman’s rho 0.327, p<0.001) and age (Spearman’s rho 0.364, p<0.001), but only weakly correlated with the extent of coronary atherosclerosis as quantified by perfusion defects (Spearman’s rho 0.123, p<0.001). Prognostically, suPAR concentrations had moderate-to-high accuracy in the prediction of cardiovascular death (AUC 0.72, 95%CI 0.62-0.81) and all-cause death (AUC 0.72, 95%CI 0.65-0.79) at 2-years, and remained a significant predictor for all-cause death after multivariable adjustment (p=0.001). SuPAR concentrations did not predict non-fatal AMI.

Conclusions: SuPAR is an independent predictor of death, but not helpful in the detection of fCAD.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are